Annals of Surgery

DOI: 10.1097/SLA.0000000000004908

Randomized Controlled Trial Comparing the Short-term Outcomes of Enhanced Recovery After Surgery and Conventional Care in Laparoscopic Distal Gastrectomy (GISSG1901)

Yulong Tian, MD,* Shougen Cao, PhD,* Xiaodong Liu, MD,* Leping Li, PhD,† Qingsi He, PhD,‡ Lixin Jiang, PhD,§ Xinjian Wang, PhD,¶ Xianqun Chu, MD,‖ Hao Wang, MD,** Lijian Xia, PhD,†† Yinlu Ding, PhD, ‡‡ Weizheng Mao, MD,§§ Xizeng Hui, PhD,¶¶ Yiran Shi, MD,‖‖ Huanhu Zhang, PhD,*** Zhaojian Niu, PhD,* Zequn Li, PhD,* Haitao Jiang, PhD,* Henrik Kehlet, MD, PhD,††† Yanbing Zhou, MD, PhD,*

* Affiliated Hospital of Qingdao University, Department of Gastrointestinal Surgery, China.

† Shandong Provincial Hospital, Department of Gastrointestinal Surgery, China.

‡ Qilu Hospital of Shandong University, Department of Gastrointestinal Surgery, China.

§ Yantai Yuhuangding Hospital, Department of Gastrointestinal Surgery, China.

¶ Weihai Central Hospital, Department of Gastrointestinal Surgery, China.

‖ Jining People's Hospital, Department of Gastrointestinal Surgery, China.

** Dongying People's Hospital, Department of Gastrointestinal Surgery, China.

†† Qianfoshan Hospital of Shandong Province, Department of Gastrointestinal Surgery, China.

‡‡ Second Hospital of Shandong University, Department of Gastrointestinal Surgery, China.

¶¶ Rizhao People's Hospital, Department of Gastrointestinal Surgery, China.

§§ Qingdao Municipal Hospital, Department of Gastrointestinal Surgery, China.

‖‖ Weifang People's Hospital, Department of Oncological Surgery, China.

*** Weihai Municipal Hospital, Department of Gastrointestinal Surgery, China.

††† Section of Surgical Pathophysiology 7621, Rigshospitalet Copenhagen University, Denmark.

Yanbing Zhou and Henrik Kehlet contributed equally to this work.

Corresponding author:

Yanbing Zhou, Department of Gastrointestinal Surgery, Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao City, China. E-mail address: zhouyanbing999@aliyun.com

Henrik Kehlet, Section of Surgical Pathophysiology 7621, Rigshospitalet Copenhagen University, Denmark. E-mail address: henrik.kehlet@regionh.dk

Author contributions: Yanbing Zhou, Henrik Kehlet and Yulong Tian conceived and designed the study; Yulong Tian and Shougen Cao drafted the manuscript; Zhaojian Niu, Zequn Li, Haitao Jiang, Xiaodong Liu completed data acquisition, data management and statistical analysis; Leping Li, Qingsi He, Lijian Xia, Lixin Jiang, Yinlu Ding, Xinjian Wang, Hao Wang, Weizheng Mao, Xizeng Hui, Yiran Shi, Huanhu Zhang, Xianqun Chu revised manuscript critically for important intellectual content; all authors have agreed to be responsible for all aspects of the work.

Abstract

Objective: This study aimed to compare the effects of ERAS and conventional programs on short-term outcomes after laparoscopic distal gastrectomy (LDG).

Summary Background Data: Currently, the enhanced recovery after surgery (ERAS) program is broadly applied in surgical areas. Although several benefits of LDG with the ERAS program have been covered, high-level evidence is still limited, specifically in advanced gastric cancer (AGC).

Methods: The present study was designed as a randomized, multicenter, unblinded trial. The enrollment criteria included histologically confirmed cT2-4aN0-3M0 gastric adenocarcinoma. Postoperative complications, mortality, readmission, medical costs, recovery and laboratory

outcomes were compared between the ERAS and conventional groups.

Results: Between April 2019 and May 2020, 400 consecutive patients who met the enrollment criteria were enrolled. They were randomly allocated to either the ERAS group (n=200) or the conventional group (n=200). After excluding patients who did not undergo surgery or gastrectomy, 370 patients were analyzed. The patient demographic characteristics were not different between the two groups. The conventional group had a significantly longer allowed day of discharge and postoperative hospital stay (6.96 vs 5.83 days, P<0.001; 8.85 vs 7.27 days, P<0.001); a longer time to first flatus, liquid intake and ambulation (3.37 vs 2.52 days, P<0.001; 3.09 vs 1.13 days, P<0.001; 2.85 vs 1.38 days, P<0.001, respectively); and higher medical costs (6826 vs 6328 $, P=0.027) than the ERAS group. Additionally, patients in the ERAS group were more likely to initiate adjuvant chemotherapy earlier (29 vs 32 days, P=0.035). There was no significant difference in postoperative complications or in the mortality or readmission rates. Regarding laboratory outcomes, the procalcitonin and C-reactive protein levels on postoperative day (POD) 3 were significantly lower and the hemoglobin levels on POD5 were significantly higher in the ERAS group than in the conventional group.

Conclusion: The ERAS program provides a faster recovery, a shorter postoperative hospitalization length, and lower medical costs after LDG without increasing complication and readmission rates. Moreover, enhanced recovery in the ERAS group enables early initiation of adjuvant chemotherapy.

Keywords: enhanced recovery after surgery, conventional care, laparoscopic distal gastrectomy, short-term outcomes, advanced gastric cancer

Globally, gastric cancer (GC) is the fifth most common cancer, and its cancer-related mortality ranks third.[1] Among GC cases, advanced gastric cancer (AGC) accounts for the majority in China.[2] The diagnosis, treatment and survival data of GC have improved dramatically over recent decades due to the introduction of new surgical techniques, chemotherapeutics and targeted drugs.[3,4] A randomized controlled trial (RCT) of laparoscopic distal gastrectomy (LDG) vs open distal gastrectomy (ODG) (KLASS-02) showed that compared with ODG patients, LDG patients had a faster recovery, fewer complications, and less pain.[5] Although LDG has been generally accepted, GC surgery remains a high-risk procedure that is significantly associated with surgical stress responses, complications and mortality.[6,7]

Enhanced recovery after surgery (ERAS) has been accepted as a standard surgical perioperative management program, and it has also developed rapidly in the field of GC.[8] ERAS refers to the adoption of a series of optimization measures to reduce stress and complications and speed up the recovery of patients during the perioperative period through multidisciplinary cooperation. Several gastrectomy studies from single medical centers using the ERAS program for GC have been reported in China, Korea and Japan.[9-12] A review of RCTs and observational studies comparing ERAS vs conventional care after gastrectomy showed that ERAS reduced postoperative hospital stay, medical costs and surgical stress and optimized recovery without increasing postoperative morbidity.[13] The formulation of ERAS guidelines after gastrectomy standardized is use in perioperative care in 2014.[14] Currently, the ERAS program is accepted by the majority of patients with GC in East Asian countries.[9-13]

Emerging evidence indicates that the ERAS program can affect prognosis after colorectal surgery and elective orthopedic surgery.[15-17] In addition, a retrospective study showed that the ERAS program improved the 5-year overall survival (OS) of patients with GC, especially those with AGC.[18] The mechanism behind this phenomenon may be related not only to the reduction of complications and surgical stress responses but also to changes in the immune response leading to higher rates of recurrence and metastasis.[19-22] However, there are still a lack of RCTs studying whether ERAS can increase the survival of patients with AGC undergoing LDG.

Based on this background, the Shandong Gastrointestinal Surgery Study Group (GISSG) designed a multicenter, randomized, unblinded controlled trial to compare the short-term outcomes and long-term prognoses of ERAS and conventional care in LDG for patients with AGC. This paper is an early result concentrating on short-term outcomes, such as complications, mortality, postoperative recovery and inflammatory indexes.

PATIENTS AND METHODS

Design, Patients, and Randomization

This study was designed as a multicenter, randomized, unblinded control trial comparing the short-term outcomes and oncologic safety of ERAS and conventional care in LDG (Chinese Clinical Trial Registry, CHiCTR1900022438), and the program used in this RCT was reported previously.[23] The primary endpoints were 3-year OS and disease-free survival (DFS). The secondary endpoints were complications, mortality, postoperative recovery, and medical costs. The exploratory results were changes in perioperative inflammatory and immune responses (leukocytes, neutrophil percentage, C-reactive protein (CRP), procalcitonin, tumor necrosis factor (TNF)-α and interleukin (IL)-6). The trial program was approved by the Affiliated Hospital of Qingdao University Ethics Committee, and all

participants signed informed consent.

Eligible participants were between 18 and 80 years of age and had pathologically proven gastric adenocarcinoma with a clinical stage of T2-4aN0-3M0. The detailed inclusion and exclusion criteria are shown in the published trial program (Table 1).

Eligible patients were randomized to the ERAS or conventional care group at a 1:1 ratio before the operation (Figure 1). The data collectors were separate from those who conducted the eligibility evaluation and recruitment of patients, and they performed the randomization with a list of randomly ordered treatment identifiers generated by a permuted block design using SAS, version 9.4 (SAS Institute Inc.). Until patients had been formally assigned to their group, the order of assignment was hidden from the surgeon who registered the patient. After randomization, the surgeons immediately informed the anesthesiologists, nurses and patients of the group assignments to carry out the different types of perioperative care. Although it was not possible to blind the doctors and patients, the radiologists, data manager and pathologists were not aware of the program received by the patients.

Surgical Quality Evaluation

To ensure surgical quality in the RCT, we conducted a rigorous evaluation of the surgeon's surgical expertise. In brief, each surgeon independently performed more than 100 laparoscopic gastrectomy procedures. At least 100 surgeries are performed by the surgeon's team each year. In addition to meeting the above conditions, surgeons submitted 6 LDGs with D2 unedited videos, and each video was recognized by five blinded evaluation experts; eventually, 13 surgeons from 13 hospitals were eligible. After starting the RCT, unedited videos and intraoperative photos of the surgical areas in LDG were collected and censored. The expert committee evaluated the surgical procedures of surgeons and, if necessary, provided surgical support to surgeons.

Surgical Procedure and Perioperative Care

First, we explored the abdominal organs and then performed standard LDG with D2 lymphadenectomy and total omentectomy. In both groups, the extents of gastrectomy and D2 lymphadenectomy were based on the Japanese gastric cancer treatment guidelines.[24] The type of reconstruction was determined by the tumor location and surgeon's preference (Billroth I/II or Roux-en-Y gastrojejunostomy). According to their own experience, surgeons could choose extracorporeal or intracorporeal methods and stapling instruments or hand sewing methods for anastomosis, but extracorporeal anastomosis using a minilaparotomy was recommended. If complications (bleeding, invasion of adjacent organs or organ injury) occurred before laparoscopic D2 lymph node dissection was completed or if the length of the

incision exceeded 10 cm, the surgery was defined convert to open.

Before surgery, gastroscopy, ultrasonic gastroscopy, chest, total abdominal, and pelvic computed tomography (CT) was performed to verify the location and size of the cancer. In addition, PET-CT is recommended for patients with suspected distant metastasis, and patients with distant metastasis were excluded according to the assessments of two seasoned radiologists. We did not routinely perform diagnostic laparoscopy with washings to stage and rule out occult metastatic disease before operation in this study. However, for all patients, we asked for taking abdominal flushing water during the operation for exfoliative cytological examination. Upper abdominal CT angiography (CTA) was performed to accurately determine the distribution of perigastric blood vessels, avoid intraoperative bleeding and vascular injury caused by vascular variation, and guide lymphadenectomy.[25] The cardiopulmonary function of patients was strictly evaluated through cardiac ultrasound and pulmonary function tests to ensure that the patients could tolerate laparoscopic surgery.

During the operation, we followed gastric cancer treatment guidelines; performed LDG and D2 lymphadenectomy; selected the appropriate reconstruction method; and recorded the intraoperative complications, blood loss, and operation time.

After the operation, all adverse events were closely observed and treated. The measures taken and the drugs used in response to the adverse events were recorded and described on the case report form (CRF). The detailed postoperative management program was previously described (Table 2).[23] Laboratory examinations were performed preoperatively and 1, 3 and 5 days postoperatively. The measurements included routine blood, kidney function, liver function, electrolyte, CRP, IL-6, procalcitonin and TNF-α tests. For patients with pathological stage II cancer or above, S-1 capsule combined with oxaliplatin was recommended for 6–8 cycles of adjuvant chemotherapy.

Definition of Surgical Complications and Mortality

The operation-related complications that occurred within the first 30 PODs were defined as early complications. Complications included intraoperative and postoperative complications. Briefly, postoperative complications included wound and pulmonary infections, gastroparesis, anastomotic leakage, lymphatic leakage, pancreatic fistulas, intra-abdominal bleeding, intraluminal bleeding, intra-abdominal abscesses, deep vein thrombosis, ileus, cholecystitis and cerebrovascular, cardiac, hepatic, and renal complications. The severity of postoperative complications was assessed in accordance with the Clavien-Dindo classification.[26]

Admission for surgery-related complications within 30 days after discharge was defined

as readmission. Any death during hospitalization or related to surgery-related complications within 30 PODs was defined as mortality.

Sample Size and Statistical Analysis

This study adopted the design of a noninferiority test, and the calculation of sample size was based on the following assumptions and historical data. The study found that the 3-year OS rate of patients who underwent radical gastrectomy under the ERAS program from 2011 to 2014 was approximately 65%.[18] Given that patient selection required 10 months, the median follow-up time will be 3 years; therefore, the noninferiority threshold was set to 1.33, according to a 1:1 random ratio. Assuming a significance level of α=0.05 (bilateral) and test efficiency of 1-β=80%, revealing that at least 178 patients would be necessary per group. A target enrollment of 400 patients was chosen to allow for a dropout rate of approximately 10%.

Categorical variables are described as numbers and percentages and were compared between groups using Pearson's chi-square test or Fisher's exact test. Continuous variables are described as the mean±standard deviation (SD). Nonnormally distributed continuous data were compared with medians and interquartile ranges, and Student's *t*-test was used for normally distributed continuous variables. Significance was defined as $P<0.05$. All statistical tests were 2-sided and performed using SPSS software version 24.0 (SPSS, Chicago, IL, USA).

RESULTS

Safety Analysis of Early Complications

After a total of 212 patients were enrolled in the RCT, the expert committee conducted the safety evaluation in January 2020. The rate of surgery-related complications was 16.4% in the ERAS group and 21.8% in the conventional group (P=0.162); therefore, the expert committee decided to continue this RCT until the full enrollment of patients was achieved (n=400).

Demographics Characteristics

Figure 1 shows the CONSORT flow diagram of patient enrollment and randomization. From April 2019 to March 2020, 400 patients were enrolled and randomly assigned to each group. After excluding 14 patients in the ERAS group and 16 patients in the conventional group, 186 patients in the ERAS group and 184 patients in the conventional group were analyzed for outcomes.

The patient demographics and baseline characteristics, including age, sex, BMI, ASA scores, NRS 2002, ECOG, comorbidities, histologic type, clinical T and N stages, and previous abdominal operations, are shown in Table 3. The characteristics of laparoscopic gastrectomy were well balanced between the ERAS and conventional groups. The completion rates of the protocol for each items were all greater than 95%, apart from anesthesia mode was 92.0% (171/186) for the ERAS group. Happily, the completion rates for the conventional group were near 100%.

Surgical, Pathologic and Postoperative Recovery Outcomes

As shown in Table 4, the time to first flatus and time to first liquid intake were significantly shorter in the ERAS group than in the conventional group (2.52 vs 3.37 days, $P < 0.001$; 1.13 vs 3.09, $P < 0.001$); moreover, the time to ambulation was significantly shorter in the ERAS group than in the conventional group (1.38 vs 2.85 days, $P < 0.001$). The allowed day of discharge and postoperative hospital stay were significantly shorter in the ERAS group than in the conventional group (5.83 vs 6.96 days, $P < 0.001$; 7.27 vs 8.85, $P < 0.001$). Readmission rates of ERAS and conventional group were revealed as 4.8% (n=9) and 4.3% (n=8) (P=0.821). Causes of readmission were 2 gastroparesis, 1 pulmonary infection, 1 pancreatic fistula, 1 intraluminal bleeding, 2 ileus, 1 kidney dysfunction, 1 cerebrovascular in the ERAS group, and 4 gastroparesis, 1 pulmonary infection , 1 hematochezia, 1 ileus, 1 poor heart function in the conventional group.

The operation time, estimated blood loss, extent of resection, LN dissection, reconstruction, intraoperative transfusion, length of incision, retrieved LN number, retrieved LNs < 15, positive margin, pT, pN, and pTNM stage were not significantly different between the groups. There was no significant difference in the exfoliated cancer cells positive rate between the two groups (8.1 vs 9.8, P=0.562). In the ERAS group, 8 patients underwent combined surgery due to cancer invasion to adjacent organs (n=6) and surgical technical problems (n=2). Additionally, patients in the ERAS group were more likely to initiate adjuvant chemotherapy earlier (29 [26-32] vs 32 [29-40] days, P=0.035). Mean medical cost was 6328 $ in the ERAS group and 6826 $ in the conventional group (P=0.027).

Surgical Complications and Mortality

Regarding surgical morbidity, the overall complications were not significantly different between the groups (16.7 % vs 21.2 % in ERAS and conventional group, P=0.266, Table 5). Intraoperative complications were also not different between the groups (4.8 % vs 5.4 %, P=0.796); notably, 22 patients in the ERAS group and 29 patients in the conventional group had postoperative complications, with no statistically significant difference between the two groups (11.8 % vs 15.8%, P=0.273). According to the Clavien-Dindo classification of

surgical complications, the distribution of severity was similar between the two groups. The mortality rate was 0 in the ERAS group and 0.5% in the conventional group (*P*=0.314). The reasons for mortality were duodenal leakage with abdominal infection.

Laboratory Outcomes

Supplemental Table 1, http://links.lww.com/SLA/D73 shows the changes in laboratory outcomes from blood samples before and after the operation. Regarding laboratory outcomes, the hemoglobin level on POD5 was significantly higher in the ERAS group (11.67 vs 11.30 g/dl *P*=0.036). However, the C-reactive protein and procalcitonin levels on the third postoperative day were significantly lower in the ERAS group (78.35 vs 90.61 mg/L *P*<0.001; 0.58 vs 0.63 ug/L *P*=0.025, respectively). White blood cell and amylase levels were similar between the groups.

DISCUSSION

This is the first and largest multicenter RCT study to evaluate the impact of the ERAS program on patient outcomes after laparoscopic gastrectomy. The short-term outcomes of this RCT show that ERAS can be safely performed by experienced surgical centers in patients who have received LDG and has the benefits of enhancing recovery and reducing medical costs, but it does not increase the rate of postoperative complications or readmission compared with the conventional care.

In our study, minimally invasive surgery, as part of the ERAS program, was performed in almost the same way in both groups, excluding possible variations in the procedure itself. At present, some prospective trials in Japan, Korea, and China have evaluated the safety and oncological feasibility of LAG for early or advanced gastric cancer, and the results have provided high-level evidence of the safety and feasibility of LAG in advanced gastric cancer.[3-5] Notably, according to the American Society of Clinical Oncology (ASCO) guidelines, patients in both groups were given adequate analgesia and early thrombus prevention although the treatment methods were not exactly the same.[23] The ERAS group were treated with basic prevention combined with antithrombotic pressure pump and low molecular weight heparin prevention. However, the conventional group did not use antithrombotic pressure pump.

In this study, the patient demographic characteristics of the two groups were similar, and the same surgical procedure was used, which led to no difference in the surgical or pathological results. However, the ERAS group had a faster postoperative recovery and a shorter hospital stay, and these results were closely related to the ERAS program. ERAS is a multimode perioperative management program designed to achieve rapid postoperative

rehabilitation, including health education, pre-rehabilitation, preoperative nutritional assessment and intervention, goal-directed fluid therapy, anesthesia mode, multimodal analgesia, early nutrition, early activity, and the removal of abdominal drainage tubes and catheters as soon as possible.[27]

The time to first flatus is often used as a simple index to evaluate the recovery of intestinal function.[13] In this study, the first time to flatus was significantly shortened in ERAS group, which implies that ERAS management leads to faster recovery of bowel function. Preoperative carbohydrates may be an important item in the ERAS items, although debatable.[27] The guidelines of the American Association of Anesthesiologists allow to intake clear fluid 2 hours preoperatively[28] which does not increase the volume of the stomach, and aspiration.[29] Surgical stress and preoperative fasting are thought to lead to insulin resistance, which may lead to hyperglycemia and may increase postoperative complications.[30] The traditional views have been that early postoperative feeding increase the risk of postoperative anastomotic leakage and pneumonia, which was not supported by our study. Epidural patient-controlled analgesia (PCA) can effectively control pain[31] and enhance patients' tolerance to mobilization and diet.[32] Thus, a meta-analysis of thoracic epidural PCA for LG showed significantly faster bowel mobilization and less pain.[33]

The results of this RCT were similar to those of previous reports that an ERAS program significantly shortened the allowed day of discharge and postoperative hospital stay.[8-13] This may be attributed to the rapid recovery of intestinal function and physical strength. In our study, the postoperative hospital stay was not evaluated alone because the postoperative hospital stay was greatly affected by external factors, so the allowed day of discharge may be more accurate.

Although the complication rate in the ERAS group decreased by 4.5%, the overall complication rates in the two groups showed no significant difference; however, we believe this result is of great significance. Our LDG was standardized by experienced surgeons and was strictly evaluated before the trial begins, so we believe that the implementation of the same surgical operation, and adherence to the ERAS program can reduce the incidence of complications.

In the laboratory examinations, CRP and procalcitonin were significantly lower on POD 3 in ERAS than in conventional group, supporting that ERAS reduces various surgical stress responses. Unfortunately, some of the participating centers did not measure interleukin-6 and TNF-α, hindering more detailed statistical analyses.

Many previous RCTs and retrospective studies with small sample sizes have suggested that the ERAS program can improve the short-term outcomes of patients with gastric

cancer.[34,35] However, this study is the first to verify these benefits in a large multicenter RCT designed for AGC patients. In particular, enhanced recovery and lower complication after LG for the patients with AGC might allow earlier adjuvant chemotherapy. In this context, our retrospective study showed that an ERAS program may increase the survival of patients with gastric cancer.[8, 18]

This RCT has several limitations. First of all, total blinding is a challenging goal to reach because the distinction in perioperative care is readily observable. Also, the surgeon's subjective consciousness may lead to bias in the results, for example, doctors subconsciously allow patients in the ERAS group to be discharged as soon as possible, thus affecting the postoperative hospital stay. Second, we did not include patients with neoadjuvant chemotherapy or high-risk patients with comorbidities. It is unknown whether the ERAS program can be applied in these patients. Third, this RCT still had abdominal drains placed in the ERAS group, which may cause surgery-related complications and lengthen hospitalization time.[36] Finally, we did not reveal the survival data of GISSG1901 which might confirm the final impact of LDG for AGC.

Despite the global success of ERAS program, many challenges lie ahead[27] with numerous ERAS factors to be further explored. In conclusion, an ERAS program provided faster recovery and less postoperative hospital stay and medical costs after LDG without increasing complication and readmission rates. Moreover, the ERAS program might offer advantages over conventional care in terms of an earlier start of adjuvant chemotherapy.

ACKNOWLEDGMENTS

We thank professor Henrik Kehlet for his support with the study design and training of investigators, co-investigators for their effort in conducting the study at the participating centres, and all the pathologists who examined the specimen.

REFERENCES

1. Bray Freddie,Ferlay Jacques,Soerjomataram Isabelle et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.[J] .CA Cancer J Clin, 2018, 68: 394-424.

2. Yang Lei,Zheng Rongshou,Wang Ning et al. Incidence and mortality of stomach cancer in China, 2014.[J] .Chin. J. Cancer Res., 2018, 30: 291-298.

3. Yu Jiang,Huang Changming,Sun Yihong et al. Effect of Laparoscopic vs Open Distal Gastrectomy on 3-Year Disease-Free Survival in Patients With Locally Advanced

Gastric Cancer: The CLASS-01 Randomized Clinical Trial. JAMA 2019; 321:1983-1992.

4. Bang Yung-Jue,Van Cutsem Eric,Feyereislova Andrea et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376:687-97.

5. Lee Hyuk-Joon,Hyung Woo Jin,Yang Han-Kwang et al. Short-term Outcomes of a Multicenter Randomized Controlled Trial Comparing Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy to Open Distal Gastrectomy for Locally Advanced Gastric Cancer (KLASS-02-RCT).[J] .Ann. Surg., 2019, 270: 983-991.

6. Hu Y, Huang C, Sun Y, et al. Morbidity and Mortality of Laparoscopic Versus Open D2 Distal Gastrectomy for Advanced Gastric Cancer: A Randomized Controlled Trial. J Clin Oncol. 2016;34(12):1350-1357. doi:10.1200/JCO.2015.63.7215

7. Inaki Noriyuki,Etoh Tsuyoshi,Ohyama Tetsuji et al. A Multi-institutional, Prospective, Phase II Feasibility Study of Laparoscopy-Assisted Distal Gastrectomy with D2 Lymph Node Dissection for Locally Advanced Gastric Cancer (JLSSG0901).[J] .World J Surg, 2015, 39: 2734-41.

8. Aarts Mary-Anne,Rotstein Ori D,Pearsall Emily A et al. Postoperative ERAS Interventions Have the Greatest Impact on Optimal Recovery: Experience With Implementation of ERAS Across Multiple Hospitals.[J] .Ann. Surg., 2018, 267: 992-997.

9. Yamada Takanobu,Hayashi Tsutomu,Cho Haruhiko et al. Usefulness of enhanced recovery after surgery programme as compared with conventional perioperative care in gastric surgery. Gastric Cancer 2012; 15:34-41.

10. Tanaka Ryo,Lee Sang-Woong,Kawai Masaru et al. programme for enhanced recovery after surgery improves short-term outcomes for patients with gastric cancer: a randomized clinical trial. Gastric Cancer 2017; 20:861-871.

11. Wang Dongsheng,Kong Ying,Zhong Bei et al. Fast-track surgery improves postoperative recovery in patients with gastric cancer: a randomized comparison with conventional postoperative care. J Gastrointest Surg 2010; 14:620-7.

12. Jeong O , Kim H G. Implementation of Enhanced Recovery after Surgery (ERAS)

Program in Perioperative Management of Gastric Cancer Surgery: a Nationwide Survey in Korea. Journal of Gastric Cancer 2019; 19(1).

13. Wee Ian Jun Yan,Syn Nicholas Li-Xun,Shabbir Asim et al. Enhanced recovery versus conventional care in gastric cancer surgery: a meta-analysis of randomized and non-randomized controlled trials.[J] .Gastric Cancer, 2019, 22: 423-434.

14. Mortensen K,Nilsson M,Slim K,et al. Consensus guidelines for enhanced recovery after gastrectomy: Enhanced Recovery After Surgery (ERAS®) Society recommendations. Br J Surg 2014;101:1209-1229.DOI:10.1002/bjs.9582

15. Gustafsson Ulf O,Oppelstrup Henrik,Thorell Anders et al. Adherence to the ERAS programme is Associated with 5-Year Survival After Colorectal Cancer Surgery: A Retrospective Cohort Study. World J Surg 2016; 40:1741-7.

16. Savaridas Terence,Serrano-Pedraza Ignacio,Khan Sameer K et al. Reduced medium-term mortality following primary total hip and knee arthroplasty with an enhanced recovery program. A study of 4,500 consecutive procedures. Acta Orthop 2013; 84:40-3.

17. Pisarska Magdalena,Torbicz Grzegorz,Gajewska Natalia et al. Compliance with the ERAS programme and 3-Year Survival After Laparoscopic Surgery for Non-metastatic Colorectal Cancer. World J Surg 2019; 43:2552-2560.

18. Yang FZ, Wang H, Wang DS, et al. Zhonghua Yi Xue Za Zhi. 2020;100(12):922-927. doi:10.3760/cma.j.cn112137-20190711-01325

19. Khuri Shukri F,Henderson William G,DePalma Ralph G et al. Determinants of long-term survival after major surgery and the adverse effect of postoperative complications. Ann Surg 2005; 242:326-41; discussion 341-3.

20. Holmgren L,O'Reilly M S,Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995; 1:149-53.

21. Oosterling SJ, van der Bij GJ, Meijer GA et al. Macrophages direct tumour histology and clinical outcome in a colon cancer model. J Pathol 2005; 207(2):147–155

22. Mantovani Alberto,Allavena Paola,Sica Antonio et al. Cancer-related inflammation. Nature 2008; 454:436-44.

23. Tian Yulong,Cao Shougen,Li Leping et al. Effects of perioperative enhanced recovery after surgery pathway management versus traditional management on the clinical outcomes of laparoscopic-assisted radical resection of distal gastric cancer: study programme for a randomized controlled trial.[J] .Trials, 2020, 21: 369.

24. Japanese Gastric Cancer Association,Japanese gastric cancer treatment guidelines 2014 (ver. 4).[J] .Gastric Cancer, 2017, 20: 1-19.

25. Shen Shuai,Cao Shougen,Jiang Haitao et al. The Short-Term Outcomes of Gastric Cancer Patients Based on a Proposal for a Novel Classification of Perigastric Arteries.[J] .J. Gastrointest. Surg., 2019, undefined: undefined.

26. Dindo Daniel., Demartines Nicolas., Clavien Pierre-Alain.(2004). Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann. Surg., 240(2), 205-13. [PMID: 15273542 DOI: 10.1097/01.sla.0000133083.54934.ae]

27. Kehlet H,Enhanced postoperative recovery: good from afar, but far from good?[J] .Anaesthesia, 2020, null: e54-e61.

28. Practice Guidelines for Preoperative Fasting and the Use of Pharmacologic Agents to Reduce the Risk of Pulmonary Aspiration: Application to Healthy Patients Undergoing Elective Procedures: An Updated Report by the American Society of Anesthesiologists Task Force on Preoperative Fasting and the Use of Pharmacologic Agents to Reduce the Risk of Pulmonary Aspiration.[J] .Anesthesiology, 2017, 126: 376-393.

29. Awad Sherif,Blackshaw Patricia E,Wright Jeff W et al. A randomized crossover study of the effects of glutamine and lipid on the gastric emptying time of a preoperative carbohydrate drink.[J] .Clin Nutr, 2011, 30: 165-71.

30. Helminen Heli,Viitanen Hanna,Sajanti Juha,Effect of preoperative intravenous carbohydrate loading on preoperative discomfort in elective surgery patients.[J] .Eur J Anaesthesiol, 2009, 26: 123-7.

31. Zhu Zhenxin., Wang Changming., Xu Chao., Cai Qingping.(2013). Influence of patient-controlled epidural analgesia versus patient-controlled intravenous analgesia on postoperative pain control and recovery after gastrectomy for gastric cancer: a prospective randomized trial. Gastric Cancer, 16(2), 193-200. doi:10.1007/s10120-012-0168-z

32. Carli Franco,Mayo Nancy,Klubien Kristine et al. Epidural analgesia enhances functional exercise capacity and health-related quality of life after colonic surgery: results of a randomized trial.[J] .Anesthesiology, 2002, 97: 540-9.

33. Khan Suhail A,Khokhar Haseeb A,Nasr A R H et al. Effect of epidural analgesia on bowel function in laparoscopic colorectal surgery: a systematic review and meta-analysis.[J] .Surg Endosc, 2013, 27: 2581-91.

34. Mingjie Xia,Luyao Zhang,Ze Tang et al. Laparoscopic Radical Gastrectomy for Resectable Advanced Gastric Cancer Within Enhanced Recovery Programs: A Prospective Randomized Controlled Trial.[J] .J Laparoendosc Adv Surg Tech A, 2017, 27: 959-964.

35. Chen Hu Jin,Xin Jiang Li,Cai Li et al. Preliminary experience of fast-track surgery combined with laparoscopy-assisted radical distal gastrectomy for gastric cancer.[J] .J. Gastrointest. Surg., 2012, 16: 1830-9.

36. Petrowsky Henrik,Demartines Nicolas,Rousson Valentin et al. Evidence-based value of prophylactic drainage in gastrointestinal surgery: a systematic review and meta-analyses.[J] .Ann. Surg., 2004, 240: 1074-84; discussion 1084-5.

FIGURE 1. CONSORT flow diagram of patient enrollment and randomization.



Table 1 Eligibility criteria for enrolling patients.

Inclusion
(1) patient's age between 18 and 80 years;
(2) histologically confirmed gastric adenocarcinoma;
(3) tumor of cT2~4aN0~3M0;
(4) tumor can be resected by distal gastrectomy in curative intention;
(5) ECOG performance status of 0 or 1;

ASA, American Society of Anesthesiology; ECOG PS, Eastern Cooperative Oncology Group performance status

Table 2 Perioperative pathway management for gastric cancer.

Programme clauses	**ERAS Group**	**Conventional Group**
Preoperative		
*Health education, exercise advice	Yes	Yes
*Organ function evaluation	Yes	Yes
*Pre-rehabilitation treatment	Yes	No
*MDT, Clinical Decision Making	Yes	Yes
*Nutritional assessment, intervention	Yes	Yes
Intestinal preparation	Enteral nutrition	No
	No mechanical bowel preparation	Mechanical intestinal preparation
*Fasting and abstinence from drinking	Fasting 6 hours before operation	Fasting and drinking
	2-hour oral glucose infusion 200 ml	for 6 hours before operation
Intraoperative		
*Intraoperative safety check (Checklist)	Yes	Yes
*Target-oriented liquid management	Yes	No
Local anesthesia in the deep incision	Local anesthesia (0.5 % ropivacaine)	No
Prevention of antibiotic use	Yes	Yes
*Surgical incision	Small midline (＜8cm) incision	Small midline (＜8cm) incision
*Precision Surgery	Laparoscopic surgery	Laparoscopic surgery

*Anesthesia mode	General anesthesia combined with	General anesthesia
	epidural anesthesiaa (T7-T9)[a]	
Intraoperative heat preservation[b]	Yes	Yes
Postoperative		
Urinary catheter	Remove within 24 hours	Routine indwelling for 1-3 days
Abdominal drainage tube	Do not place or remove early	Remove it before discharge[c]
	after operation as far as possible	
Gastric tube	No	Retention for 1-3 days[d]
*Early bedside activity	Start soberly and plan your activities	2-3 days after operation
*Postoperative analgesia	Multimodal analgesia[e]	Opioids[f]
*Target-oriented liquid management	Yes	No
Prevention of deep venous thrombosis	Basic, physical and drug prevention	Basic and drug prevention
*Early EN after operation	Sequential EN treatment after awakening	Gradually start EN after exhaust

Notes: * Core provisions of perioperative ERAS pathway management.

Abbreviations: NSAID, Non-steroidal anti-inflammatory drugs; EN, Enteral nutrition; ERAS: enhanced recovery after surgery.

a dose/drug: ropivacaine 500mg + lidocaine 400mg and liquid velocity: 2ml / h

b Heat preservation measures: pre-heating fluid replenishment, thermal blanket, heater

c Extubation indication: The drainage fluid is light red or clear, 24 hours less than 20 ml and no pancreatic and lymphatic fistula

d The criteria of removal of nasogastric tube: Recovery of intestinal peristalsis, anal exhaust and oral clear fluid

e Multimodal analgesia: POD1~2 patient controlled epidural analgesia (Lidocaine + Ropivacaine), POD3~5 regular oral paracetamol 0.65g q8h 50mg when the VAS≥4 flurbiprofen 50mg is injected intravenously.

f Opioids: POD1~2 Tramadol 50mg q8h, when the VAS≥4 tramadol 50mg is injected intravenously (dose ≤ 400mg/d).

Table 3 Patient demographics and baseline characteristics.

Variables	ERAS	Conventional (n=184)	*P* Value
Age, year±SD	58.3±10.5	58.6±10.9	0.305
Gender			0.685
Male, n (%)	129 (69.4)	124 (67.4)	
Female, n (%)	57 (30.6)	60(32.6)	
BMI, kg/m^2±SD	23.6±3.2	23.7±3.3	0.351
ASA score			0.804
I, n (%)	98 (50.0)	93 (50.5)	
II, n (%)	74 (39.8)	79 (42.9)	
III, n (%)	14 (7.5)	12 (6.5)	
NRS 2002			0.757
<3, n (%)	89 (47.8)	91 (49.5)	
>=3, n (%)	97 (52.2)	93 (50.5)	
ECOG			0.609
0, n (%)	121 (65.1)	115 (62.5)	
1, n (%)	65 (34.9)	69 (37.5)	
Comorbidity			0.686
None, n (%)	112 (60.2)	107 (58.2)	
One or more, n (%)	74 (39.8)	77 (41.8)	
Histologic type			0.651
Well, n (%)	14 (7.5)	14 (7.6)	
Moderate, n (%)	56 (30.1)	60 (32.6)	
Poor, n (%)	116 (62.4)	110 (59.8)	
cT stage			0.761
cT2, n (%)	61 (32.8)	54 (29.3)	
cT3, n (%)	40 (21.5)	43 (23.4)	
cT4a, n (%)	85 (45.7)	87 (47.3)	
cN stage			0.759
cN0, n (%)	35 (18.8)	27 (14.7)	
cN1, n (%)	38 (20.4)	38 (20.7)	
cN2, n (%)	39 (21.0)	41 (25.5)	
cN3, n (%)	74 (39.8)	78 (41.8)	
Previous abdominal operation, n (%)	28 (15.1)	22 (12.0)	0.384

BMI: Body Mass Index; ASA: American Society of Anesthesiologists; ERAS: enhanced recovery after surgery; NRS: nutrition risk screening; ECOG: Eastern Cooperative Oncology Group.

[a] Pathologic stage according to the American Joint Committee on Cancer, 7th Edition.

Table 4 Surgical, pathologic and recovery outcomes for ERAS and conventional group.

Variables	ERAS (n=186)	Conventional (n=184)	*P* Value
Operation time (min±SD)	204.12±45.81	208.41±44.56	0.242
Estimated blood loss (ml±SD)	88.54±37.15	92.82±40.17	0.207
Extent of resection			0.470
Total gastrectomy, n (%)	10 (5.4)	7 (3.8)	
Distal gastrectomy, n (%)	176 (94.6)	177 (96.2)	
Operation method			0.262
Total laparoscopic gastrectomy	24 (12.9)	17 (9.2)	
Laparoscopic assisted gastrectomy	162 (87.1)	167 (90.8)	
Combined operation	8 (4.3)	7 (3.8)	0.808
LN dissection			0.442
<D2	9 (4.8)	6 (3.3)	
D2	177 (95.2)	178 (96.7)	
Reconstruction			0.570
Billroth-I, n (%)	7 (3.8)	11 (6.0)	
Billroth-II, n (%)	54 (29.0)	49 (26.6)	
Roux-en-Y, n (%)	125 (67.2)	124 (67.4)	
Intraoperative transfusion, n (%)	8 (4.3)	11 (6.0)	0.465
Length of incision (cm±SD)	7.18±1.45	7.27±1.51	0.482
Retrieved LN number (mean±SD)	32.76±13.08	32.81±13.54	0.617
Retrieved LNs < 15	7 (3.8)	5 (2.7)	0.570
Positive margin	2 (1.1)	1 (0.5)	0.569
Exfoliated cancer cells positive	15 (8.1)	18 (9.8)	0.562
pT stage			0.445
T1	24 (12.9)	15 (8.2)	
T2	41 (22.0)	35 (19.0)	
T3	44 (23.7)	43 (23.4)	

T4a	71 (38.2)	84 (45.7)	
T4b	6 (3.2)	7 (3.8)	
pN stage			0.582
N0	37 (19.9)	29 (15.8)	
N1	41 (22.0)	35 (19.0)	
N2	46 (24.7)	44 (23.9)	
N3a	42 (22.6)	48 (26.1)	
N3b	20 (10.8)	28 (15.2)	
pTNM stage			0.564
I	41 (22.0)	34 (18.5)	
II	77 (41.4)	74 (40.2)	
III	68 (36.6)	76 (41.3)	
Time to first flatus (days±SD)	2.52±0.83	3.37±1.28	<0.001
Time to first liquid intake (days±SD)	1.13±0.51	3.09±1.14	<0.001
Time to ambulation (days±SD)	1.38±0.58	2.85±1.42	<0.001
Remove the drainage tube (days±SD)	2.36±1.91	4.17±1.28	<0.001
Allowed day of discharge (days±SD)	5.83±1.42	6.96±1.63	<0.001
Postoperative hospital stay (days±SD)	7.27±1.83	8.85±2.18	<0.001
30-day readmission, n (%)	9 (4.8)	8 (4.3)	0.821
Surgical procedure-adjuvant chemotherapy interval,	29 (26-32)	32 (29-40)	0.035
median (IQR), days			
Medical cost (dollars±SD)	6328±925	6826±1174	0.027

ERAS: enhanced recovery after surgery; IQR, interquartile range.

Table 5 Postoperative complications and mortality.

Variables	ERAS Group	Conventional Group	*P*
Intraoperative complication, n	9 (4.8)	10 (5.4)	0.796
Postoperative complication, n	22 (11.8)	29 (15.8)	0.273
Wound infection, n (%)	2 (1.1)	2 (1.1)	1.000
Pulmonary, n (%)	6 (3.2)	10 (5.4)	0.296
Gastroparesis, n (%)	2 (1.1)	4 (2.2)	0.403
Anastomotic leakage, n (%)	2 (1.1)	3 (1.6)	0.644
Lymphatic leakage, n (%)	0 (0.0)	1(0.5)	0.314
Pancreatic fistula, n (%)	1 (0.5)	2 (1.1)	0.556
Intra-abdominal bleeding, n	1 (0.5)	1 (0.5)	1.000
Intraluminal bleeding, n (%)	3 (1.6)	2 (1.1)	0.661
Intra-abdominal abscess, n (%)	1 (0.5)	1 (0.5)	1.000
Deep vein thrombosis, n (%)	0 (0.0)	0 (0.0)	-
Ileus, n (%)	2 (1.1)	1 (0.5)	0.569
Cerebrovascular, n (%)	1 (0.5)	0 (0.0)	0.319
Cardiac, n (%)	0 (0.0)	1 (0.5)	0.314
Cholecystitis, n (%)	0 (0.0)	0 (0.0)	-
Hepatic, n (%)	0 (0.0)	1 (0.0)	-
Renal, n (%)	1 (0.5)	0 (0.0)	0.319
Overall morbidity	31 (16.7)	39 (21.2)	0.266
Mortality, n (%)	0 (0.0)	1 (0.5)	0.314
Clavien-Dindo classification			
I, n (%)	6 (3.2)	5 (2.7)	0.773
II, n (%)	17 (9.1)	21 (11.4)	0.471
III, n (%)	6 (3.2)	7 (4.9)	0.763
IV, n (%)	2 (1.1)	3 (1.6)	0.644
V, n (%)	0 (0.0)	1 (0.5)	0.314

ERAS: enhanced recovery after surgery.